PALAZZO, ANTONELLA
 Distribuzione geografica
Continente #
NA - Nord America 1.438
EU - Europa 375
AS - Asia 192
AF - Africa 34
SA - Sud America 2
Totale 2.041
Nazione #
US - Stati Uniti d'America 1.436
IT - Italia 135
DE - Germania 80
SG - Singapore 71
SE - Svezia 67
IN - India 58
CN - Cina 55
FI - Finlandia 39
TG - Togo 31
UA - Ucraina 21
GB - Regno Unito 6
IE - Irlanda 6
RU - Federazione Russa 5
RO - Romania 4
BG - Bulgaria 3
FR - Francia 3
ID - Indonesia 3
AR - Argentina 2
AM - Armenia 1
BD - Bangladesh 1
CA - Canada 1
EE - Estonia 1
EG - Egitto 1
IL - Israele 1
IR - Iran 1
IS - Islanda 1
MX - Messico 1
NL - Olanda 1
PL - Polonia 1
RS - Serbia 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
TW - Taiwan 1
ZA - Sudafrica 1
Totale 2.041
Città #
Fairfield 270
Woodbridge 120
Ashburn 113
Chandler 108
Seattle 99
Cambridge 97
Wilmington 91
Houston 83
Ann Arbor 64
Rome 56
Singapore 39
Princeton 38
Dearborn 34
Lomé 31
Plano 31
San Paolo di Civitate 30
Lawrence 27
Beijing 26
San Diego 19
Munich 16
Des Moines 15
Boston 14
Millbury 14
Fremont 11
Andover 7
Dublin 6
Helsinki 6
Jacksonville 6
Milan 6
Grafing 5
Hefei 5
Nanjing 5
Naples 5
Latina 4
New York 4
Norwalk 4
Redmond 4
Bremen 3
Bühl 3
Jakarta 3
San Mateo 3
Santa Clara 3
Sofia 3
Boardman 2
Dallas 2
Falls Church 2
Federal 2
Guangzhou 2
Hangzhou 2
Jinan 2
Kunming 2
London 2
Los Angeles 2
Redwood City 2
Varedo 2
Baotou 1
Berlin 1
Bratislava 1
Caivano 1
Chicago 1
Dalmine 1
Dhaka 1
Düsseldorf 1
Frankfurt 1
Fuzhou 1
Gunzenhausen 1
Haifa 1
Harbin 1
Indiana 1
Jönköping 1
Kilburn 1
Lanzhou 1
Lappeenranta 1
Laurel 1
Leawood 1
Mexico City 1
Muizenberg 1
Nanchang 1
Nanning 1
Phoenix 1
Piediluco 1
Pune 1
Reykjavik 1
Roda 1
San Pablo 1
Shenyang 1
Simi Valley 1
Southend 1
Taipei 1
Tallinn 1
Terni 1
Toronto 1
Voluntari 1
Zhengzhou 1
Totale 1.594
Nome #
Treatment of peritoneal carcinomatosis from breast cancer by maximal cytoreduction and HIPEC: A preliminary report on 5 cases 93
Clinical outcome and prognostic factors in renal medullary carcinoma: a pooled analysis from 18 years of medical literature 87
Neo-adjuvant and adjuvant chemotherapy in bladder cancer. 86
Circulating tumor cells count and characterization in a male breast cancer patient 84
Abiraterone acetate in castration-resistant prostate cancer 82
Genital and inguinal cutaneous toxicity in male and female patients treated with sunitinib 81
Multimodality Treatment of Gynecomastia in Patients Receiving Antiandrogen Therapy for Prostate Cancer in the Era of Abiraterone Acetate and New Antiandrogen Molecules 80
Clinical and Pathological Features of Primary Neuroectodermal Tumor/Ewing Sarcoma of the Kidney 78
Breast cancer "tailored follow-up" in Italian oncology units: a web-based survey. 78
Is postoperative computed tomography evaluation a prognostic indicator in patients with optimally debulked advanced ovarian cancer? 76
Clinical and pathological features of primary renal angiosarcoma. 75
Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy 73
Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies 72
Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials. 72
Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials 71
null 70
Past, Present and Future of Targeted Therapy in Solid Tumors 67
Outcome and medial presentation of breast cancer: European Institute of Oncology experience 63
Management of Metastatic Renal Cell Carcinoma Progressed After Sunitinib or Another Antiangiogenic Treatment. 63
Renal cell carcinoma: incidence and cost estimation in the era of targeted therapy. 58
Neoadjuvant targeted therapy in renal cell carcinoma 58
Reply to"mTOR inhibitor-related pulmonary toxicity;incidence even higher" 57
Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant. 57
Erlotinib in metastatic non-small cell lung cancer (NSCLC) patients unselected for Epidermal Growth Factor Receptors (EGFR) mutations: a retrospective analysis of elderly patients 53
Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients 49
How circulating tumor cells escape from multidrug resistance: translating molecular mechanisms in metastatic breast cancer treatment. 47
Palbociclib plus fulvestrant or everolimus plus exemestane for pretreated advanced breast cancer with lobular histotype in ER+/HERr2− patients: A propensity score-matched analysis of a multicenter retrospective patient series 42
Umbilical node as first clinical appearance in a patient with a high tumor burden. 40
Circulating tumor cells and "suspicious objects" evaluated through CellSearch® in metastatic renal cell carcinoma. 37
PEMETREXED-RELATED RENAL TOXICITY IN PATIENTS (PTS) WITH THORACIC MALIGNANCIES 36
Dermatomyositis as first clinical appearance for a thymic epidermoid cell carcinoma. 30
Incidence and risk of pulmonary toxicity in patients treated with mTOR ihibitors for malignancy. A meta-analysis of published trials 29
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study 28
Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer 13
Totale 2.085
Categoria #
all - tutte 5.576
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.576


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020467 0 0 0 27 51 78 85 62 71 48 24 21
2020/2021140 16 27 5 7 6 19 2 13 16 12 8 9
2021/2022299 6 21 37 4 34 6 5 40 16 33 41 56
2022/2023394 70 113 13 37 45 55 1 8 33 2 14 3
2023/2024153 4 19 8 9 15 15 1 12 0 31 27 12
2024/202574 7 20 32 15 0 0 0 0 0 0 0 0
Totale 2.085